Paradigm Biocapital Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Paradigm Biocapital Advisors’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$180M	Hold	2,562,154	–	–	3.67%	8
2025 Q4	$210M	Sell	2,562,154 -103,544	-4%	-$7.73M	5.35%	5
2025 Q3	$158M	Sell	2,665,698 -310,401	-10%	-$15.3M	4.51%	5
2025 Q2	$121M	Buy	2,976,099 +365,902	+14%	+$16.5M	5.15%	5
2025 Q1	$134M	Buy	2,610,197 +78,301	+3%	+$3.87M	6.14%	6
2024 Q4	$140M	Buy	2,531,896 +91,451	+4%	+$4.15M	4.88%	6
2024 Q3	$80.3M	Buy	2,440,445 +5,029	+0.2%	+$141K	2.72%	9
2024 Q2	$66.2M	Sell	2,435,416 -427,990	-15%	-$14.4M	2.53%	14
2024 Q1	$104M	Buy	2,863,406 +1,838,406	+179%	+$54.1M	3.66%	11
2023 Q4	$20.8M	Buy	+1,025,000	New	+$17.1M	0.97%	22

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Paradigm Biocapital Advisors's TARS Position: Q1 2026 in Review

Paradigm Biocapital Advisors held its Tarsus Pharmaceuticals (TARS) position steady in Q1 2026 at 2,562,154 shares worth $180M. The position accounts for 3.67% of the portfolio, ranked #8.

Paradigm Biocapital Advisors first reported a position in TARS in Q4 2023 and has held it in 10 quarters since. The position peaked at $210M in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

Paradigm Biocapital Advisors held 2,562,154 shares of Tarsus Pharmaceuticals worth $180M as of Q1 2026.
Paradigm Biocapital Advisors left its Tarsus Pharmaceuticals share count unchanged in Q1 2026.
Tarsus Pharmaceuticals made up 3.67% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #8 holding.
Paradigm Biocapital Advisors first reported a position in Tarsus Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Paradigm Biocapital Advisors's Tarsus Pharmaceuticals position peaked at $210M in Q4 2025.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.